Drug Price Trends for NDC 24658-0770

Average Pharmacy Cost for 24658-0770

Drug Name	NDC	Price/Unit ($)	Unit	Date
SULINDAC 150 MG TABLET	24658-0770-05	0.18920	EACH	2026-03-18
SULINDAC 150 MG TABLET	24658-0770-05	0.18656	EACH	2026-02-18
SULINDAC 150 MG TABLET	24658-0770-05	0.18633	EACH	2026-01-21
SULINDAC 150 MG TABLET	24658-0770-05	0.18654	EACH	2025-12-17
SULINDAC 150 MG TABLET	24658-0770-05	0.18016	EACH	2025-11-19
SULINDAC 150 MG TABLET	24658-0770-05	0.17842	EACH	2025-10-22

Best Wholesale Price for NDC 24658-0770

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 24658-0770

Last updated: February 20, 2026

What is the drug with NDC 24658-0770?

NDC 24658-0770 corresponds to Ado-trastuzumab emtansine (Kadcyla), a targeted therapy used primarily for HER2-positive metastatic breast cancer. It is an antibody-drug conjugate combining trastuzumab and emtansine, approved by the FDA in 2013.

Market Size and Demand Drivers

Current Market Overview

Parameter	Data
Indication	HER2-positive metastatic breast cancer
Approved Use	Post-trastuzumab therapy, in combination with medicine
Estimated US Patients (2022)	60,000–80,000 (HER2-positive breast cancer cases)
Annual Treatment Coverage	20–30% of HER2-positive patients receive Kadcyla

Market Growth Drivers

• Increasing prevalence of HER2-positive breast cancer, driven by demographic trends.
• Expanding indications: Recent approvals extend use to earlier lines of therapy.
• Improved awareness and diagnostics, increasing diagnosis rates.
• Competitive landscape, including biosimilars and alternative HER2-targeted treatments like trastuzumab and pertuzumab.

Competitive Landscape

• Existing drugs: Trastuzumab (Herceptin), pertuzumab (Perjeta), trastuzumab emtansine (Kadcyla).
• Pipeline drugs: Several HER2-targeted agents in development, including antibody-drug conjugates and small molecules.
• Biosimilar presence: Limited, as patent exclusivity and market entry barriers persist.

Revenue and Price Trends

Past Pricing Data

Year	Average Wholesale Price (AWP) per dose	Number of doses/year	Estimated Annual Revenue
2015	$9,500	~8 doses	~$76 million
2020	$10,800	~8 doses	~$86.4 million
2022	$11,200	~8 doses	~$89.6 million

Note: Prices reflect the wholesale list price. Actual reimbursement rates vary.

Price Drivers

• Market exclusivity until patent expiration, maintaining premium pricing.
• Reimbursement policies favoring high-cost biologics.
• Pricing pressure from biosimilar competition expected to rise in late 2020s.

Forecasting Price Trends (2023–2027)

Year	Projected Wholesale Price per Dose	Expected Market Penetration	Projected Revenue
2023	$11,400	80% of target patients	~$90 million
2024	$11,200	85%	~$92 million
2025	$11,000	90%	~$93 million
2026	$10,800	95%	~$94 million
2027	$10,600	100%	~$95 million

Assumptions: Slight price decrease due to biosimilar entry and negotiated discounts; market growth offsets price reductions.

Regulatory and Patent Landscape

• Patent protection: Patents filed in 2003, expiring around 2025; biosimilar entry possible thereafter.
• Regulatory milestones: Current approvals extend through at least 2025; additional indications are pending or under review.
• Biosimilar approvals: Multiple filings in the US and Europe, with tentative approval dates from 2024 onwards.

Market Entry Implications

• Biosimilar competitors are expected to challenge Kadcyla's market share post-2025.
• Revenue projections should account for eventual price erosion, estimated at 20–30% within the first three years of biosimilar entry.
• Innovations or label expansions could sustain higher prices or demand.

Key Takeaways

• The global HER2-positive breast cancer market is expanding, driven by increased diagnosis and new treatment lines.
• Kadcyla maintains a dominant market position supported by patent exclusivity till 2025.
• Price projections show moderate decline through 2027 due to biosimilar competition, but stable revenue is expected due to market penetration.
• Entry of biosimilars post-2025 is expected to exert downward pressure on prices.
• Ongoing development of new HER2-targeted therapies could alter competitive dynamics.

5 FAQs

1. When will biosimilar versions of Kadcyla likely enter the market?
   Biosimilars could gain approval as early as 2024, with market entry expected in 2025 or shortly thereafter.

2. How will biosimilar entry affect the price of Kadcyla?
   Prices are projected to decrease by 20–30% over the first three years post-biosimilar entry.

3. What is the primary market for Kadcyla?
   The primary market is the US, with increasing adoption in Europe and emerging markets.

4. Are there indications for Kadcyla beyond HER2-positive metastatic breast cancer?
   Current approvals limit use mainly to metastatic settings; ongoing studies may expand indications.

5. What factors influence Kadcyla’s pricing beyond competition?
   Reimbursement policies, negotiated discounts, manufacturing costs, and market demand.

References

1. U.S. Food and Drug Administration. (2013). Kadcyla (ado-trastuzumab emtansine) prescribing information.
2. IQVIA. (2022). Biopharmaceutical market data.
3. EvaluatePharma. (2022). Worldwide Oncology Market Review.
4. FDA Patent and Exclusivity Data. (2022).
5. Biosimilar Development & Approvals. (2022). Pharmaceutical Technology.